{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '12', 'APPENDICES', '12.1', 'List of Cautionary Concomitant Medications', 'The following list describes medications and foods that are common strong inhibitors/inducers', 'of CYP3A, CYP2C8 and p-glycoprotein (P-gp) inhibitors that should be avoided, used with', 'caution, or closely monitored. This list should not be considered all inclusive; consult', 'individual drug labels for specific information. If there are concerns or questions about', 'concomitant use of any drugs listed below, discussion with the sponsor is encouraged.', 'P-gp Inhibitors', 'Strong CYP3A', 'Strong CYP3A4', 'Strong CYP2C8', 'Strong CYP2C8', 'Inhibitors', 'Inducers', 'Inhibitors', 'Inducers', 'amiodarone', 'boceprevir', 'carbamazepine', 'clopidogrel', 'rifampin', 'carvedilol', 'cobicistat', 'enzalutamide', 'gemfibrozil', 'clarithromycin', 'conivaptan', 'mitotane', 'drenedarone', 'danoprevir/', 'phenytoin', 'itraconazole', 'ritonavir', 'rifampin', 'lapatinib', 'elvitegravir/', \"St John's wort\", 'lopinavir/ritonavir', 'ritonavir', 'propafenone', 'grapefruit juice', 'quinidine', 'indinavir/ritonavir', 'ranolazine', 'itraconazole', 'saquinavir/ritonavir', 'ketoconazole', 'telaprevir', 'lopinavir/ritonavir', 'tipranavir/ritonavir', 'paritaprevir/', 'verapamil', 'ritonavir/', '(ombitasvir and/or', 'dasabuvir)', 'posaconazole', 'ritonavir', 'saquinavir/', 'ritonavir', 'telaprevir', 'tipranavir/ritonavir', 'troleandomycin', 'voriconazole', 'Note: Any additional strong inhibitors/inducers of CYP3A, CYP2C8, and P-gp inhibitors that are identified or become', 'commercially available while the clinical trial in ongoing are also applicable. P-gp: p-glycoprotein', 'Table 10', 'Summary of Potential Drug Reactions', 'Arm A: EV', 'Arm B: Docetaxel', 'Arm B:', 'Arm B: Paclitaxel', 'Vinflunine', 'Strong CYP3A4', 'Closely monitor', 'Should avoid', 'Should avoid', 'Exercise caution', 'inhibitor', 'Strong CYP3A4', 'Should avoid', 'Should avoid', 'Exercise caution', 'inducer', 'P-gp inhibitor', 'Closely monitor', 'Strong CYP2C8', 'Exercise caution', 'inhibitor/inducer', 'EV: enfortumab vedotin; P-gp: p-glycoprotein', \"Additional information for inhibitors/inducers can be found in FDA's guidance (Drug\", 'Interaction and Labeling).', 'https://www fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664 ht', 'm#table5-2', '14 Sep 2020', 'Astellas', 'Page 103 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '12.2', 'Liver Safety Monitoring and Assessment', 'Any subject enrolled in a clinical study with active drug therapy and reveals an increase of', 'serum aminotransferases (AT) to > 3 X ULN (to > 5 X ULN in subjects with liver metastases) or', 'bilirubin > 2 X ULN should undergo detailed testing for liver enzymes (including at least ALT,', 'AST, ALP, and TBL). Testing should be repeated within 72 hours of notification of the test', 'results. For studies for which a central laboratory is used, alerts will be generated by the central', 'laboratory regarding moderate and severe liver abnormality to inform the investigator, study', 'monitor and study team. Subjects should be asked if they have any symptoms suggestive of', 'hepatobiliary dysfunction.', 'Definition of Liver Abnormalities', 'Confirmed abnormalities will be characterized as moderate and severe where ULN:', 'ALT or AST', 'Total Bilirubin', 'Moderate', '>', '3 X ULN (in patients without liver', 'or', '> 2 X ULN', 'metastases), > 5 X ULN (in patients with', 'liver metastases)', 'Severe', '> 3 X ULN', 'and', '> 2 X ULN', 'In addition, the subject should be considered to have severe hepatic abnormalities for any of', 'the following:', 'ALT or AST > 8 X ULN.', 'ALT or AST > 5 X ULN for more than 2 weeks (in the absence of liver metastases).', 'ALT or AST > 3 X ULN and International Normalized Ratio (INR) > 1.5 (If INR testing', 'is applicable/evaluated).', 'ALT or AST > 3 X ULN with the appearance of fatigue, nausea, vomiting, right upper', 'quadrant pain or tenderness, fever, rash and/or eosinophilia (> 5%).', 'The investigator may determine that abnormal liver function results, other than as described', 'above, may qualify as moderate or severe abnormalities and require additional monitoring and', 'follow-up.', 'Follow-up Procedures', 'Confirmed moderate and severe abnormalities in hepatic functions should be thoroughly', 'characterized by obtaining appropriate expert consultations, detailed pertinent history, physical', 'examination and laboratory tests. The site should complete the liver abnormality case report', 'form (LA-CRF) that has been developed globally and can be activated for any study or', 'appropriate document. Subjects with confirmed abnormal liver function testing should be', 'followed as described below.', 'Confirmed moderately abnormal LFTs should be repeated 2 to 3 times weekly then weekly or', 'less if abnormalities stabilize or the study drug has been discontinued and the subject is', 'asymptomatic.', '14 Sep 2020', 'Astellas', 'Page 104 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}